We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Digital Pathology Solution Resolves the Tissue Floater Conundrum

By LabMedica International staff writers
Posted on 30 Jul 2020
Print article
Image: The Aperio AT2 is the ideal digital pathology slide scanner for high-throughput clinical laboratories, delivering precise eSlides with low rescan rate (Photo courtesy of Leica Biosystems).
Image: The Aperio AT2 is the ideal digital pathology slide scanner for high-throughput clinical laboratories, delivering precise eSlides with low rescan rate (Photo courtesy of Leica Biosystems).
In routine clinical practice, pathologists may encounter extraneous pieces of tissue on glass slides that could be because of contamination from other specimens. These are typically called tissue floaters. The dilemma pathologists often face is whether such a tissue floater truly belongs to the case in question, or if instead it represents a true contaminant from another patient’s sample in which case it should be ignored.

There are currently several measures a pathologist can employ to troubleshoot the tissue floater problem. Akin to forensic analysis, some laboratories have implemented molecular techniques (e.g., DNA fingerprinting for tissue identity testing) to try resolve this problem by dissecting, testing, and then comparing the molecular results of the tissue floater to the adjacent patient sample on the glass slide.

Clinical Pathologists at the University of Michigan (Ann Arbor, MI, USA) and their colleagues demonstrated the feasibility of using an image search tool to resolve the tissue floater conundrum. A glass slide was produced containing two separate hematoxylin and eosin (H&E)-stained tissue floaters. This fabricated slide was digitized along with the two slides containing the original tumors used to create these floaters. These slides were then embedded into a dataset of 2,325 whole slide images comprising a wide variety of H&E stained diagnostic entities. Digital slides were broken up into patches and the patch features converted into barcodes for indexing and easy retrieval. A deep learning-based image search tool was employed to extract features from patches via barcodes, hence enabling image matching to each tissue floater.

All three slides were then entirely digitized at ×40 magnification using an Aperio AT2 whole slide scanner (Leica Biosystems, Richmond, IL, USA). The quality of these digital slides was checked to avoid inclusion of unique identifiers All the slides were then entirely digitized at ×40 magnification using an Aperio AT2 scanner. The quality of these digital slides was checked to avoid inclusion of unique identifiers. These whole slide images (WSIs) included cases from a wide variety of anatomic sites (e.g., colon, brain, thyroid, prostate, breast, kidney, salivary gland, skin, soft tissue, etc.) exhibiting varied diagnostic pathologic entities (i.e., reactive, inflammatory, benign neoplasms, and malignancies).

The scientists reported that there was a very high likelihood of finding a correct tumor match for the queried tissue floater when searching the digital database. Search results repeatedly yielded a correct match within the top three retrieved images. The retrieval accuracy improved when greater proportions of the floater were selected. The time to run a search was completed within several milliseconds. The image search results for matching tissue floaters when using the UPMC 300 WSI pilot dataset showed that the median rank best result for both the bladder and colon tumor was 1 (95% CI =1) when selecting 5% up to 100% of the floater region.

The authors concluded that using an image search tool offers pathologists an additional method to rapidly resolve the tissue floater conundrum, especially for those laboratories that have transitioned to going fully digital for primary diagnosis. The study was published on July 15, 2020 in the journal Archives of Pathology & Laboratory Medicine.



New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Unstirred Waterbath
HumAqua 5
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Karius Focus BAL is designed to quickly identify the etiology of lung infections and improve diagnostic yield over standard of care testing (Photo courtesy of Karius)

Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections

Bronchoalveolar lavage (BAL) is a commonly used procedure for diagnosing lung infections, especially in immunocompromised patients. However, standard tests often fail to pinpoint the exact pathogen, leading... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.